Javanese Turmeric and the Liver: Rich Rodent Evidence, No Human Trials, and a Regulatory Warning That Cuts the Other Way

The main Curcuma zanthorrhiza page already gives the liver claim an honest reading: “a plausible mechanism, a consistent animal signal, and no adequately powered, properly blinded human trial establishing benefit for a liver condition.” Researching this page in more depth confirms that verdict and adds two things the main page does not have room for: the actual named studies and doses behind the animal signal, and a genuine internal tension — the same choleretic mechanism that gives temulawak its liver reputation is also the reason the European medicines regulator advises against using it in liver disease. A herb marketed for liver support and a regulator warning it off in liver disease is not a contradiction once you see the mechanism; it is the mechanism cutting both ways.

Table of Contents

  1. The Claim
  2. The Rodent Hepatoprotection Literature, By Study
  3. A More Clinically Relevant Model: Chemotherapy-Induced Liver Injury
  4. A Separate Thread: Liver Lipids and Triglycerides
  5. A Different Question Entirely: Xanthorrhizol Against Liver Cancer Cells
  6. Why Oral Dosing May Not Reach the Liver at All
  7. The Regulatory Warning: Why the EU Advises Against Use in Liver Disease
  8. The Turmeric Liver-Injury Signal, and Whether It Applies Here
  9. Verdict and Evidence Tier
  10. What Is Not Known
  11. Safety Facts From the Evidence
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Claim

Liver support is temulawak’s single most-repeated traditional indication. Jamu sellers market it for jaundice, hepatitis and generic “liver weakness,” and it is the use that drove most of the twentieth-century Indonesian and Korean research programmes into the plant. It is also the use where the gap between laboratory evidence and clinical proof is widest, and where a reader with actual liver disease has the most to lose from over-trusting an animal result.

The Rodent Hepatoprotection Literature, By Study

The foundational work is Lin and colleagues (1995), who tested an extract of Curcuma xanthorrhiza at 100 mg/kg body weight in mice against two classic hepatotoxin models — acetaminophen (paracetamol) and carbon tetrachloride (CCl4), given by injection into the abdomen, both standard ways of inducing acute chemical liver injury in a laboratory animal. Pre-treated animals showed significantly lower serum transaminases (alanine aminotransferase (ALT)/aspartate aminotransferase (AST), the enzymes that leak into blood when liver cells rupture) than untreated injured animals, confirmed histologically: less necrosis and vascular congestion, and more binuclear hepatocytes in the mid-zone, a sign of active liver regeneration.

Devaraj and colleagues (2014), working at Universiti Sains Malaysia, repeated the CCl4 model with a standardized extract and went further by fractionating it: the fractions were compared for antioxidant activity in vitro (in the test tube), the hexane fraction had the strongest antioxidant activity, and only that fraction was then tested in rats at 125, 250 and 500 mg/kg against CCl4-induced damage — with improved liver-function markers, improved antioxidant liver enzymes, reduced lipid peroxidation, and good histological recovery. The authors explicitly link the antioxidant and hepatoprotective findings, which is a coherent mechanism, and explicitly frame the goal as validating temulawak as a “functional food for hepatitis remedy” — language worth flagging as aspirational, since nothing in the study tested actual hepatitis, viral or otherwise.

A 2025 paper by Lister and colleagues (Iranian Journal of Basic Medical Sciences) is a cell-culture study, not an animal study: a Curcuma xanthorrhiza extract was added to HepG2 cells (a human liver cancer cell line) injured with acetaminophen. The extract lowered the inflammatory signals IL-1β and IL-6 and nitric oxide, raised IL-10, and lowered the cell-death markers caspase-3 and caspase-9 and the stress kinase JNK, with the strongest effect at 125 µg/mL. The consistent thread across three independent groups, spanning three decades — two rodent studies and one cell-culture study — is: toxin-challenge models, an antioxidant mechanism, and a real, reproducible protective signal against acute chemical injury. None of the three tested a spontaneous, chronic, or infectious liver disease — the kind an actual patient has.

Back to Table of Contents

A More Clinically Relevant Model: Chemotherapy-Induced Liver Injury

The most clinically suggestive preclinical work is Kim and colleagues’ series (2004–2005) on cisplatin, a chemotherapy drug whose dose-limiting toxicities include both liver and kidney injury in real cancer patients. Oral xanthorrhizol at 200 mg/kg in mice attenuated cisplatin-induced hepatotoxicity in one paper (200 mg/kg/day by mouth for 4 days before a 45 mg/kg cisplatin injection; xanthorrhizol blocked the cisplatin-induced DNA binding of the inflammatory switch NF-κB and partly lowered the inflammatory enzymes iNOS and COX-2) and cisplatin-induced nephrotoxicity in a companion paper, with a follow-up mechanistic study tracing the protective effect partly to attenuated phosphorylation of c-Jun N-terminal kinases (JNKs), a stress-signalling pathway implicated in cisplatin’s organ toxicity.

This is more clinically suggestive than the CCl4 work for one reason: cisplatin toxicity is a real problem oncologists manage in real patients, not a laboratory-only insult. It is still, without qualification, a mouse study. The 2004 authors suggested that combining xanthorrhizol with cisplatin “may provide more advantage” than cisplatin alone in cancer therapy; that idea has not been tested in people. Nobody has tested whether xanthorrhizol or temulawak protects human cancer patients from cisplatin’s liver or kidney effects, and the drug-interaction and cytochrome-P450 findings discussed in the chemistry deep-dive raise a concern specifically for people on chemotherapy.

A Separate Thread: Liver Lipids and Triglycerides

A distinct line of rat work, mostly from Yasni and colleagues in the early 1990s, looked at liver fat rather than liver injury. Rats fed a diet containing 4% powdered Curcuma xanthorrhiza rhizome showed inhibited liver fatty acid synthase activity and reduced liver triglyceride content; a 1994 follow-up found that the essential oil (0.02% of the diet) lowered liver triglycerides without changing serum triglycerides, while the hexane-soluble fraction (0.5%) lowered both serum and liver triglycerides; the fraction containing α-curcumene (about 65% of the essential oil) suppressed fatty-acid synthesis in cultured rat liver cells, and the authors named it one of the active principles. A separate 1993 paper from the same group reports effects on serum and liver lipids alongside curcuminoids more broadly.

This is a real, named-compound finding, and it is worth keeping conceptually separate from the antioxidant hepatoprotection story above — a different proposed mechanism (lipid synthesis inhibition rather than free-radical scavenging), a different outcome measure (triglyceride content rather than transaminases), and no attempt in these papers to connect the two. Whether reduced liver fat in a rat on a 4%-temulawak diet says anything about fatty liver disease in a human eating an occasional cup of the traditional drink is untested and, given the dose gap discussed below, doubtful.

Back to Table of Contents

A Different Question Entirely: Xanthorrhizol Against Liver Cancer Cells

One further xanthorrhizol/liver finding needs to be kept sharply distinct from everything above: a 2012 paper reports that xanthorrhizol induces DNA fragmentation in HepG2 cells — a human liver cancer cell line — involving Bcl-2 family apoptosis proteins. This is a cancer-cytotoxicity finding, mechanistically the mirror image of hepatoprotection: it is evidence that xanthorrhizol can kill malignant liver cells in a dish, not evidence that it protects healthy liver tissue. The two claims sound adjacent because both involve the word “liver,” and conflating them would be a straightforward category error. This finding belongs with the anticancer literature discussed on the chemistry deep-dive, not with hepatoprotection, and is noted here only to head off the confusion.

Why Oral Dosing May Not Reach the Liver at All

The European Medicines Agency’s formal pharmacokinetic review of curcumin — conducted for the regulatory assessment discussed in full on the digestion and regulatory deep-dive — is directly relevant here and rarely mentioned alongside the hepatoprotection literature. Curcumin has poor systemic bioavailability after oral dosing: in rats given a single 2 g dose, plasma concentrations stayed below 5 µg/mL, and roughly 60–75% of an oral dose is excreted unchanged in the faeces. In a human Phase I study, a daily oral dose of 3.6 g of curcumin produced detectable but low levels in colorectal tissue — and the reviewers found “negligible distribution of the parent drug to hepatic tissue or other tissues beyond the gastrointestinal tract.”

That finding, from gram-scale human dosing of the shared curcuminoid constituent, is a real problem for the plausibility of an oral hepatoprotective effect at any dose an ordinary person would actually take. It does not by itself rule out a systemic effect from xanthorrhizol, which has different chemistry and its own (separately measured, low) oral bioavailability of roughly 10–13% in a 2022 rat and mouse pharmacokinetic study — but it means the rodent hepatoprotection data above, mostly conducted with injected or high-dose oral extract rather than a cup of tea, cannot be assumed to translate to traditional-strength human consumption without direct evidence, which does not exist.

Back to Table of Contents

The Regulatory Warning: Why the EU Advises Against Use in Liver Disease

This is the finding most worth surfacing on its own, because it runs directly against the marketing. The European Medicines Agency’s Committee on Herbal Medicinal Products (HMPC) reviewed Curcuma xanthorrhiza rhizome in 2014 and issued a formal traditional-use monograph — discussed fully on the companion deep-dive — whose special-warnings section states, verbatim:

“Due to the possible stimulation on bile secretion, Curcuma xanthorrhiza is not recommended in case of obstruction of the bile duct, cholangitis, liver disease, gallstones and any other biliary diseases.”

Read that list again: liver disease is on it. The regulatory body that formally certified temulawak’s traditional digestive use, working from the same choleretic pharmacology that underlies the liver-support folklore, concluded that stimulating bile flow in a person whose liver is already diseased is a reason for caution, not a reason to recommend it. This is not a contradiction in the data — it is one mechanism (increased bile secretion and gallbladder contraction) correctly read as beneficial in a healthy digestive system and potentially harmful in a compromised one, exactly the “benefit and hazard are one property described twice” pattern that recurs across choleretic and cholagogue herbs generally. For a reader with diagnosed liver disease, this warning matters more than the animal hepatoprotection data.

Back to Table of Contents

The Turmeric Liver-Injury Signal, and Whether It Applies Here

The main page already discusses a separate, more recently documented risk: a growing case series of drug-induced liver injury (DILI) attributed to concentrated Curcuma supplements, catalogued through the US Drug-Induced Liver Injury Network (ten cases reported in 2023, with a follow-up 2025 review on the broader diagnostic challenge of herb-induced liver injury). In the 2023 report the ten cases were enrolled between 2004 and 2022, all of them since 2011; the injury was mostly hepatocellular (damage to the liver cells themselves, 9 of 10), five people were hospitalised and one died of acute liver failure, symptoms began 1 to 4 months after first use, and 7 of the 10 carried the gene marker HLA-B*35:01. One precise point is worth adding: these case reports are about products labelled and marketed as “turmeric” — which in Western commerce means Curcuma longa in the overwhelming majority of cases, not Curcuma xanthorrhiza. None of the located DILI case reports specify Javanese turmeric as the implicated species.

This does not clear temulawak. Curcuminoids are shared chemistry between the two species (at lower concentration in C. xanthorrhiza, as the main page already establishes), piperine (black pepper) was present in 3 of the 7 products chemically tested in the case series, and piperine-enhanced-absorption formulations raise curcuminoid absorption regardless of which Curcuma species supplies them, and the human leukocyte antigen-B*35:01 genetic-susceptibility marker reported in some cases would apply to any curcuminoid-containing product in a susceptible individual. The honest position is that the mechanism generalises even though the specific case reports do not name this species — which is precisely why the jaundice, dark-urine and unusual-fatigue warning already on the main page belongs on any concentrated Curcuma xanthorrhiza extract taken regularly, not only on products explicitly labelled turmeric.

Back to Table of Contents

Verdict and Evidence Tier

Back to Table of Contents

What Is Not Known

  1. No human trial has tested temulawak, in any preparation, against any diagnosed liver condition — hepatitis (viral or otherwise), fatty liver disease, cirrhosis, or drug-induced injury.
  2. No dose-finding data exist connecting the animal-protective doses (100–500 mg/kg extract, well above traditional intake once body-weight-scaled) to any human-achievable exposure.
  3. No data establish whether the rodent-model protection generalises from acute chemical insult to the chronic, low-grade liver injury patterns (steatosis, fibrosis) that affect most people who would seek out a “liver herb.”
  4. No safety data exist for using concentrated temulawak extract specifically in a person who already has liver disease — the regulatory warning above is a caution based on mechanism, not a study that tested and found harm, and so the safety question in this group is open.
  5. No study has isolated whether it is xanthorrhizol, the curcuminoids, or another rhizome constituent responsible for the antioxidant hepatoprotective signal in the whole-extract studies; the Devaraj 2014 fractionation points toward the hexane (essential-oil-rich) fraction but does not identify a single active compound.

Safety Facts From the Evidence

For people with a diagnosed liver condition, the regulatory warning above is the key fact on this page, more than the animal hepatoprotection studies: the European Medicines Agency’s monograph lists Curcuma xanthorrhiza as not recommended in liver disease, biliary obstruction, cholangitis or gallstones — the one regulatory body that has formally reviewed its pharmacology for exactly this purpose. The animal data come from short-term chemical injury, not from the liver diseases people actually have. Jaundice (yellow skin or eyes), dark urine, pale stools, itching, unusual fatigue and right-upper-abdominal pain are signs of liver injury that hospitals treat as urgent, regardless of which Curcuma species is in the product; in the turmeric case series, symptoms began 1 to 4 months after first use. For people on chemotherapy or another drug with a narrow therapeutic index (where a small change in blood level matters), a concentrated extract can change drug levels through the cytochrome-P450 interactions discussed in the chemistry deep-dive.

Back to Table of Contents

Key Research Papers

  1. Lin SC, Lin CC, Lin YH, Supriyatna S, Teng CW. Protective and therapeutic effects of Curcuma xanthorrhiza on hepatotoxin-induced liver damage. The American Journal of Chinese Medicine. 1995;23(3–4):243–254. The foundational acetaminophen/CCl4 hepatoprotection study in mice. — PubMed PMID: 8571920
  2. Devaraj S, Ismail S, Ramanathan S, Yam MF. Investigation of antioxidant and hepatoprotective activity of standardized Curcuma xanthorrhiza rhizome in carbon tetrachloride-induced hepatic damaged rats. The Scientific World Journal. 2014;2014:353128. The hexane-fraction dose-response study. — PubMed PMID: 25133223
  3. Kim SH, Hong KO, Chung WY, Hwang JK, Park KK. Abrogation of cisplatin-induced hepatotoxicity in mice by xanthorrhizol is related to its effect on the regulation of gene transcription. Toxicology and Applied Pharmacology. 2004;196(3):346–355. The chemotherapy-injury model. — PubMed PMID: 15094305
  4. Hong KO, Hwang JK, Park KK, Kim SH. Phosphorylation of c-Jun N-terminal Kinases (JNKs) is involved in the preventive effect of xanthorrhizol on cisplatin-induced hepatotoxicity. Archives of Toxicology. 2005;79(4):231–236. The JNK mechanism follow-up. — PubMed PMID: 15536542
  5. Yasni S, Imaizumi K, Nakamura M, Aimoto J, Sugano M. Effects of Curcuma xanthorrhiza Roxb. and curcuminoids on the level of serum and liver lipids, serum apolipoprotein A-I and lipogenic enzymes in rats. Food and Chemical Toxicology. 1993;31(3):213–218. The liver-lipid thread. — PubMed PMID: 8473006
  6. Yasni S, Imaizumi K, Sin K, Sugano M, Nonaka G, Sidik. Identification of an active principle in essential oils and hexane-soluble fractions of Curcuma xanthorrhiza Roxb. showing triglyceride-lowering action in rats. Food and Chemical Toxicology. 1994;32(3):273–278. The α-curcumene follow-up. — PubMed PMID: 8157222
  7. Kang J, Won J, Hwang JK, Kang W. Bioavailability of xanthorrhizol following oral administration of a supercritical extract of Java turmeric. Food Science and Biotechnology. 2022;31(10):1309–1313. The low oral-bioavailability finding (10–13% in rats and mice). — PubMed PMID: 35992318
  8. Tee TT, Cheah YH, Meenakshii N, Mohd Sharom MY, Azimahtol Hawariah LP. Xanthorrhizol induced DNA fragmentation in HepG2 cells involving Bcl-2 family proteins. Biochemical and Biophysical Research Communications. 2012;420(4):834–838. The liver-cancer-cell finding, distinct from hepatoprotection. — PubMed PMID: 22465013
  9. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver injury associated with turmeric — a growing problem: ten cases from the Drug-Induced Liver Injury Network. The American Journal of Medicine. 2023;136(2):200–206. The DILI signal — about products labelled turmeric, discussed above for species precision. — PubMed PMID: 36252717
  10. Halegoua-DeMarzio D, Navarro V. Challenges in herbal-induced liver injury identification and prevention. Liver International. 2025;45(3):e16071. The 2025 follow-up on diagnosing herb-induced liver injury generally. — PubMed PMID: 39136211
  11. Lister INE, Chiuman L, Mutia MS, Hartono H, Girsang E, Sutendi AF, Kusuma HSW, Hadiprasetyo DS, Widowati W. Hepatoprotective effects of Curcuma xanthorrhiza Roxb. extract via free radical scavenger, inhibiting apoptosis and inflammation mechanisms in acetaminophen-induced liver injury. Iranian Journal of Basic Medical Sciences. 2025;28(8):1100–1106. HepG2 cell-culture study. — PubMed PMID: 40584441
  12. Curcuma xanthorrhiza and hepatoprotection — live search, both spellings. — Search PubMed

Connections

Back to Table of Contents